These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30681344)

  • 1. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
    Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
    Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of Candesartan Cilexetil: 2-Hydroxypropyl-β-Cyclodextrin Interactions: A Computational Approach Using Steered Molecular Dynamics Simulations.
    Kiriakidi S; Mavromoustakos T
    Methods Mol Biol; 2021; 2207():45-70. PubMed ID: 33113127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.
    Ntountaniotis D; Kellici T; Tzakos A; Kolokotroni P; Tselios T; Becker-Baldus J; Glaubitz C; Lin S; Makriyannis A; Mavromoustakos T
    Biochim Biophys Acta; 2014 Oct; 1838(10):2439-50. PubMed ID: 24946142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
    Fotakis C; Megariotis G; Christodouleas D; Kritsi E; Zoumpoulakis P; Ntountaniotis D; Zervou M; Potamitis C; Hodzic A; Pabst G; Rappolt M; Mali G; Baldus J; Glaubitz C; Papadopoulos MG; Afantitis A; Melagraki G; Mavromoustakos T
    Biochim Biophys Acta; 2012 Dec; 1818(12):3107-20. PubMed ID: 22906712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.
    Kiriakidi S; Chatzigiannis C; Papaemmanouil C; Tzakos AG; Mavromoustakos T
    Biochim Biophys Acta Biomembr; 2020 Mar; 1862(3):183142. PubMed ID: 31830465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
    Shaikh SM; Avachat AM
    Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
    Amer AM; Allam AN; Abdallah OY
    AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System.
    de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J
    AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K; Inada Y; Nishikawa K
    Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the clinical pharmacology of candesartan cilexetil.
    Gavras H
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):25S-30S. PubMed ID: 10678285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin II receptor antagonists: candesartan cilexetil].
    Naka T; Kubo K; Nishikawa K; Inada Y; Furukawa Y
    Yakugaku Zasshi; 2000 Dec; 120(12):1261-75. PubMed ID: 11193378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T
    Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of the orientation of selected drugs with 2-hydroxylpropyl-β-cyclodextrin using 2D-NMR spectroscopy and molecular modeling.
    Adhikari S; Daftardar S; Fratev F; Rivera M; Sirimulla S; Alexander K; Boddu SHS
    Int J Pharm; 2018 Jul; 545(1-2):357-365. PubMed ID: 29747001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid self-microemulsifying formulation for candesartan cilexetil.
    Nekkanti V; Karatgi P; Prabhu R; Pillai R
    AAPS PharmSciTech; 2010 Mar; 11(1):9-17. PubMed ID: 20013081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.